Strategic Investment Advisors MI Has $2.28 Million Stake in Pfizer Inc. (NYSE:PFE)

Strategic Investment Advisors MI reduced its stake in Pfizer Inc. (NYSE:PFE) by 4.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 86,031 shares of the biopharmaceutical company’s stock after selling 4,293 shares during the period. Strategic Investment Advisors MI’s holdings in Pfizer were worth $2,282,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of PFE. AQR Capital Management LLC boosted its position in shares of Pfizer by 1.6% in the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock valued at $17,068,000 after acquiring an additional 9,435 shares during the period. MidWestOne Financial Group Inc. boosted its position in shares of Pfizer by 1.5% in the second quarter. MidWestOne Financial Group Inc. now owns 26,530 shares of the biopharmaceutical company’s stock valued at $742,000 after acquiring an additional 386 shares during the period. Ascent Group LLC boosted its position in shares of Pfizer by 23.2% in the second quarter. Ascent Group LLC now owns 50,845 shares of the biopharmaceutical company’s stock valued at $1,423,000 after acquiring an additional 9,565 shares during the period. Aviso Wealth Management boosted its position in shares of Pfizer by 0.7% in the second quarter. Aviso Wealth Management now owns 80,848 shares of the biopharmaceutical company’s stock valued at $2,262,000 after acquiring an additional 573 shares during the period. Finally, Forefront Analytics LLC boosted its position in shares of Pfizer by 17.0% in the second quarter. Forefront Analytics LLC now owns 15,049 shares of the biopharmaceutical company’s stock valued at $421,000 after acquiring an additional 2,189 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Stock Performance

NYSE:PFE opened at $26.10 on Monday. The company has a market capitalization of $147.89 billion, a PE ratio of 35.27, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a 50 day simple moving average of $26.11 and a two-hundred day simple moving average of $27.94. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.17) EPS. Research analysts anticipate that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.59%. This is a boost from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio is presently 227.03%.

Insiders Place Their Bets

In other news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average cost of $28.24 per share, for a total transaction of $28,240.00. Following the acquisition, the director now directly owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America reissued a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Guggenheim cut their price objective on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. UBS Group cut their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research report on Wednesday, January 8th. Finally, Truist Financial cut their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.